Pfizer Inc

The chart remains in a healthy uptrend that is pausing into key support. Price is holding above the 20-day EMA and rising 50-day SMA, and pullbacks on light volume look constructive. Medium-term bias stays bullish while awaiting clear acceptance of support or a breakout above resistance. Tactical entries should be deferred until price confirms strength in the $26.25–$27.75 zone.

• ↑Q2 revenue $15B (+1% YoY; +5% ex-COVID) beats estimates, EPS $0.77.
• ↑Raised FY26 guidance to $60.5–62.5B after strong Q2 execution.
• ↓COVID revenue set to fall to ~$4B in 2026, reducing top-line growth.